Promising drug targets to be identified by game-changing technology

By admin Nov25,2023

The Thermo Scientific Orbitrap Astral Mass Spectrometer (MS) will be located at MIPS in Parkville and is the second to be installed in Australia and the first to be stationed within an academic institution. 

The new instrument provides faster throughput, higher sensitivity, and deeper coverage when studying the proteome to identify proteins previously undetectable, therefore accelerating scientific discoveries with greater efficiency. 

It will form the basis for the recently established Drug Target Identification Platform (DTIP) led by associate professor Darren Creek from MIPS and funded through a $3 million grant from the Commonwealth Government’s Medical Research Future Fund.  

Urgent unmet need

MIPS has identified an urgent unmet need for target identification capabilities to support Australia’s drug discovery pipeline. It says many promising biomedical discoveries fail to progress to clinical therapeutics due to poor efficacy – often underpinned by a lack of understanding about their mechanism of action.

Creek said: “Our primary objective is to establish a dedicated platform based on state-of-the-art omics technologies to support the Australian drug discovery community and provide an efficient and unbiased avenue to identify drug targets and biomarkers. 

“The Orbitrap Astral MS will allow us to detect more proteins at a much faster rate and with more accuracy than what was previously possible. In a nutshell, it will enable us to dramatically expand the scale and scope of our experiments and, ultimately, help to provide an efficient avenue to identify drug targets for a broad range of diseases.” 

By admin

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *